API | pyrotinib

pyrotinib Report issue

Small molecule Experimental

AACT ChEMBL PubChem

Active Ingredient History

NOW

Chemistry

SMILES: CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C
InChIKey: SADXACCFNXBCFY-IYNHSRRRSA-N
Mol. Mass: 583.09
ALogP: 6.47 Partition coefficient
ChEMBL Molecules:

pyrotinib

pyrotinib

More Chemistry

Pharmacology

Mechanisms of Action:
- Epidermal growth factor receptor (Homo sapiens) ^UniProt
- Receptor tyrosine-protein kinase erbB-2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

pyrotinib

Organizations (31)

Research & Development (31)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (19)

Approved Indications (1)

Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (19)

Brain Neoplasms (Phase 2)

Breast Diseases (Phase 2)

Breast Neoplasms (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Colorectal Neoplasms (Phase 2)

Drugs, Investigational (Phase 2)

Drug Therapy, Combination (Phase 1/Phase 2)

Esophageal Neoplasms (Phase 2)

Genes, erbB-2 (Phase 2)

Healthy Volunteers (Phase 1)

Intestinal Neoplasms (Phase 2)

Neoadjuvant Therapy (Phase 2)

Neoplasms (Phase 2)

Pharmacokinetics (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Stomach Neoplasms (Phase 2)

Treatment Outcome (Phase 2)

Triple Negative Breast Neoplasms (Phase 1/Phase 2)

Vinorelbine (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 134
# of Trial Organizations: 31

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue